ClinicalTrials.gg
CompletedNCT02064387Updated Aug 11, 2020Results posted

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

A Phase 1 interventional study of GSK2857916 in Multiple Myeloma, sponsored by GlaxoSmithKline. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
17th of 49
79 · median 50
Started
2014
the only one that year
Phase 1
11 of 49
3 open now
Registered
1st of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 17th largest by enrollment, is the only one that started in 2014, is one of 11 in phase 1, and was the 1st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA). The hypothesis is that GSK2857916 can be safely administered to subjects with MM and with BCMA positive malignancies at doses where target engagement can be demonstrated. This study will determine if adequate target engagement of BCMA receptors translates into clinical benefit for subjects with MM and BCMA positive lymphomas. The study will consists of two parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The study will enroll a total of approximately 80-95 subjects with relapsed/refractory MM or BCMA-expressing hematologic malignancies. The maximum dose to be administered in this trial will not exceed 5 milligram/kilogram(mg/kg).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • BCMA expressing Lymphomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed written , which includes compliance with the requirements and restrictions listed in the consent form.
  • Male or female, 18 years or older (at the time consent is obtained)
  • (ECOG) performance status of 0 or 1.
  • Part 1/dose escalation; or cytologically confirmed diagnosis of Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within 60 days of completion of the last therapy.

Part 2 /MM cohort; Histologically or cytologically confirmed diagnosis of: Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within 60 days of completion of the last therapy, and has with at least one of the following: serum M-protein >=0.5 gram (g)/decilitre (dL) (>=5 g/Litre (L)), urine M-protein >=200 milligram (mg)/24hour (h).

Serum free light chain (FLC) assay: Involved FLC level >=5 mg/dL (>=50 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65) and proven plasmacytoma (should be measured within 28 days of Screening Visit).

  • Part 2/Other BCMA positive Hematologic cohort: Subject with one of the following lymphomas: Diffuse Large B-cell Lymphoma (DLBCL) or follicular lymphoma (FL) that exhibits positive BCMA expression on tumor cells as determined by a central laboratory using a validated Immunohistochemistry (IHC) assay. Eligible subjects with BCMA positive malignancies must also fulfill the prior treatment requirements as follows: DLBCL: at least 2 containing at least one line of chemo-immunotherapy with anti-CD20 antibody, and either has undergone stem cell transplant or is considered transplant ineligible. FL: at least 2 prior lines of systemic therapy.
  • Subjects with a history of stem cell transplant are eligible for study participation provided the following eligibility criteria are met: transplant was > 100 days prior to study enrolment, no active infection; subject meets the remainder of the eligibility criteria outlined in the study protocol.
  • Adequate organ system functions as defined below >=1.0x10\^9/L, >=8.0 g/dL, >=50x10\^9/L, international normalized ration () \<=1.5, Partial thromboplastin time \<=1.5xupper limit of normal (), total \<=1.25xULN, and aspartate aminotransferase\<=1.5 X ULN, serum creatinine or calculated \<1.2XULN >=60 mL/min for Part 1;>=50 mL/minute (min) for Part 2 if data supports loosening criteria, Albuminuria\<=500 mg/24h, >=50%, Troponin\<=1xULN, Calcium\<=1.1xULN
  • A female subject is eligible to participate if she is of: Non- or women of childbearing potential must have a negative serum pregnancy test within 72 hours of first dose of study treatment and agree to use effective during the study and for 60 days following the last dose of study treatment.
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of first dose of study until 60 days after the last dose of study treatment to allow for clearance of any altered sperm
  • All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events, version 4) must be \<=Grade 1 at the time of enrollment except for alopecia, and grade 2 neuropathy.

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-tumor therapy within 14 days, or plasmapheresis within 7 days prior to the first dose of study drug
  • Use of an drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drug.
  • History of an stem cell transplant. Subjects with a history of an autologous stem cell transplant are NOT excluded if they meet inclusion criteria related to history of autologous stem cell transplant.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfil the inclusion criteria related to organ system function.
  • Evidence of active mucosal or internal bleeding
  • Any major surgery within the last four weeks.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with subject's safety, obtaining or compliance to the study procedures.
  • Known active infection requiring antibiotic treatment
  • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal or cardiac disease
  • Subjects with previous or concurrent are allowed only if the second tumor is not contributing to the subject's illness. The subject must not be receiving active therapy, other than hormonal therapy for this disease and the disease must be considered medically stable for at least 2 years.
  • Evidence of cardiovascular risk including any of the following: corrected>=470 millisecond, evidence of current uncontrolled arrhythmias, history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening, Class III or IV heart failure as defined by the functional classification system, uncontrolled hypertension, subjects with intra-cardiac defibrillators or permanent pacemakers, abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to GSK2857916 or any of the components of the study treatment.
  • Pregnant or lactating female.
  • Known human immuno virus infection.
  • Subjects with positive test for surface (HBS-Ag) or Hepatitis B core (HBc)antigen
  • Subjects with positive test for (HCV) infection are excluded regardless of viral load. If hepatitis C antibody test is positive, a confirmatory polymerase chain reaction (PCR) or Recombinant immunoblot assay (RIBA) test should be performed. If the PCR or RIBA test is negative, subject is eligible for this trial
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver or otherwise stable chronic liver disease per investigator's assessment).
  • Current corneal disease or a history of corneal disease.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Schedule 1 Part 1

    Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.

    Drug: GSK2857916

  • Experimental
    Schedule 2 Part 1

    Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.

    Drug: GSK2857916

  • Experimental
    Schedule 1 Part 2

    Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.

    Drug: GSK2857916

  • Experimental
    Schedule 2 Part 2

    Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.

    Drug: GSK2857916

Interventions

  • A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

    Time frame: Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)

  2. Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

    Time frame: Up to 35 months (maximum duration of follow-up from first dose to last contact or death)

  3. Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

    Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  4. Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1

    An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria\>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting\>=7 days, febrile neutropenia lasting\>=72 hours, Grade\>=3 thrombocytopenia associated with bleeding where estimated blood loss is\>10 milliliter orGrade4 thrombocytopenia lasting\>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.

    Time frame: Up to Day 21 (from first dose)

  5. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1

    Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\<120 millimeters of mercury\[mmHg\], 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  6. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)

    Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  7. Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)

    Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg \[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg \[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  8. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1

    The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 beats per minute \[bpm\] and increase to \>100 bpm) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  9. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)

    The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  10. Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)

    The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  11. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  12. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  13. Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)

    Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  14. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1

    Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  15. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)

    Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  16. Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)

    Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  17. Number of Participants With Grade Change From Baseline in Hematology Data-Part 1

    Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  18. Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)

    Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  19. Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)

    Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  20. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1

    Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  21. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)

    Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  22. Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)

    Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  23. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1

    Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  24. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)

    Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  25. Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)

    Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

    Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  26. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2 and 3)

  27. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2)

  28. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)

  29. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)

  30. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)

  31. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)

  32. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)

  33. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

  34. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)

    Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

    Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

  35. Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)

    Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.

    Time frame: Baseline and Day 1 (Cycle 2)

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  2. AUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  3. Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  4. AUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  5. Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  6. AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  7. Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  8. CL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  9. Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  10. Cmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  11. Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)

  12. Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

  13. Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  14. t1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  15. Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  16. Vss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  17. Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  18. Tmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  19. Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

  20. Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2

    Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)

  21. AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  22. AUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  23. Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  24. Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  25. Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)

  26. Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)

  27. Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

    Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)

  28. Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg

    Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

    Time frame: Pre-dose and EOI of Day 1 (Cycle 1)

  29. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

    Time frame: Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)

  30. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

    Time frame: Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)

  31. Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)

    Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

    Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)

  32. Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.

    Time frame: Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

  33. Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

    Time frame: Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

  34. Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)

    Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

    Time frame: Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)

  35. Overall Response Rate (ORR)- Part 1

    ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).

    Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)

  36. ORR-Part 2 (MM)

    ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.

    Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)

  37. ORR-Part 2 (NHL)

    Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.

    Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)

  38. Clinical Benefit Rate (CBR)- Part 1

    CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).

    Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)

  39. CBR- Part 2

    CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.

    Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)

07

Results

Posted Sep 26, 2019

Participant flow

This is a Phase1 study of antibody drug conjugate GSK2857916 in participants with relapsed/refractory multiple myeloma(MM) or non-hodgkin's lymphoma (NHL).The study was conducted in 2 parts-Part1(dose escalation) and Part2(dose expansion).The starting dose in Part1 was 0.03mg/kg GSK2857916 given once every three weeks; 1cycle=21 days for 16cycles.

Part 1 Max 23.5 Months Followup Duration
Participant flow — Part 1 Max 23.5 Months Followup Duration
MilestonePart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)
Started114443483600
Completed114443462500
Not completed000000021100
Withdrew: Death000000010100
Withdrew: Lost to follow-up000000010000
Withdrew: Withdrawal by subject000000001000
Part 2 Max 35 Months Followup Duration
Participant flow — Part 2 Max 35 Months Followup Duration
MilestonePart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)
Started0000000000356
Completed0000000000293
Not completed000000000063
Withdrew: Death000000000053
Withdrew: Withdrawal by subject000000000010

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

Time frame:
Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Common non-SAE1144334836
Any SAE0011102413
PrimaryNumber of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

Time frame:
Up to 35 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Common non-SAE35
Any SAE17
PrimaryNumber of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.

Time frame:
Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Common non-SAE6
Any SAE3
PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1

An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria\>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting\>=7 days, febrile neutropenia lasting\>=72 hours, Grade\>=3 thrombocytopenia associated with bleeding where estimated blood loss is\>10 milliliter orGrade4 thrombocytopenia lasting\>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.

Time frame:
Up to Day 21 (from first dose)
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 10000000000
PrimaryNumber of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1

Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\<120 millimeters of mercury\[mmHg\], 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
DBP, any grade increase0121233534
SBP, any grade increase0122313725
PrimaryNumber of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)

Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
DBP, any grade increase30
SBP, any grade increase31
PrimaryNumber of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)

Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg \[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg \[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
DBP, any grade increase5
SBP, any grade increase5
PrimaryNumber of Participants With Change From Baseline in Heart Rate and Temperature-Part 1

The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 beats per minute \[bpm\] and increase to \>100 bpm) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
HR, decrease to <600021001413
HR, change to normal or no change0002101311
HR, increase to >1001121332112
Temp, decrease to <=350000000000
Temp, change to normal or no change1134424826
Temp, increase to >=380010010010
PrimaryNumber of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)

The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
HR, decrease to <609
HR, change to normal or no change17
HR, increase to >10010
Temp, decrease to <=351
Temp, change to normal or no change29
Temp, increase to >=385
PrimaryNumber of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)

The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
HR, decrease to <603
HR, change to normal or no change2
HR, increase to >1001
Temp, decrease to <=350
Temp, change to normal or no change5
Temp, increase to >=381
PrimaryNumber of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1

Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Gl, Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,60011404604
Gl, Hyper,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,60000002000
Gl, Hyper,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,60000000000
Gl, Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,60001000102
Gl, Hypo,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,60000000000
Gl, Hypo,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,60000000000
Albumin,any grade increase,n=1,1,4,4,4,3,4,8,3,60012311112
Albumin,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
Albumin,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
ALP,any grade increase,n=1,1,4,4,4,3,4,8,3,60001101225
ALP,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
ALP,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
ALT,any grade increase,n=1,1,4,4,4,3,4,8,3,60012101515
ALT,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
ALT,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
AST,any grade increase,n=1,1,4,4,4,3,4,8,3,60122113635
AST,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
AST,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
T.Bil.,any grade increase,n=1,1,4,4,4,3,4,8,3,60000000020
T.Bil.,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
T.Bil.,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
CK,any grade increase,n=1,1,4,4,3,3,4,8,3,60001000333
CK,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,60000000100
CK,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,60000000000
Creat,any grade increase,n=1,1,4,4,4,3,4,8,3,60020111000
Creat,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
Creat,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
GGT,any grade increase,1,1,4,4,3,3,4,8,3,60011103334
GGT,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,60001000100
GGT,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,60000000000
Pot,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,60010000000
Pot,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60010000000
Pot,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Pot,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,60011120112
Pot,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60000000000
Pot,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Mg,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,60001000000
Mg,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60000000000
Mg,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Mg,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,60010100303
Mg,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60000000000
Mg,Hypo,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
Ph,any grade increase,n=1,1,4,4,4,3,4,8,3,60021001000
Ph,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
Ph,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,60000000000
Sod,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,60000000100
Sod,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60000000000
Sod,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Sod,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,60112213203
Sod,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60010000002
Sod,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Urate,any grade increase,n=1,1,4,4,4,3,4,8,3,60100010000
Urate,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,60000000000
Urate,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60100010000
Ca,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,60010113201
Ca,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60010001000
Ca,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
Ca,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,60000000021
Ca,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,60000000000
Ca,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,60000000000
PrimaryNumber of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)

Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Gl, Hyperglycemia,any grade increase,n=3519
Gl, Hyperglycemia,increase to Grade 3,n=350
Gl, Hyperglycemia,increase to Grade 4,n=350
Gl, Hypoglycemia,any grade increase,n=351
Gl, Hypoglycemia,increase to Grade 3,n=350
Gl, Hypoglycemia,increase to Grade 4,n=350
Albumin,any grade increase,n=3515
Albumin,increase to Grade 3,n=352
Albumin,increase to Grade 4,n=350
ALP,any grade increase,n=3519
ALP,increase to Grade 3,n=350
ALP,increase to Grade 4,,n=350
ALT,any grade increase,n=3519
ALT,increase to Grade 3,n=350
ALT,increase to Grade 4,n=350
AST,any grade increase,n=3529
AST,increase to Grade 3,n=353
AST,increase to Grade 4,n=350
Total bilirubin,any grade increase,n=353
Total bilirubin,increase to Grade 3,n=350
Total bilirubin,increase to Grade 4,n=350
CK,any grade increase,n=3515
CK,increase to Grade 3,n=351
CK,increase to Grade 4 ,n=350
Creatinine,any grade increase,n=357
Creatinine,increase to Grade 3,n=350
Creatinine,increase to Grade 4,n=350
GGT,any grade increase,n=3421
GGT,increase to Grade 3,n=346
GGT,increase to Grade 4,n=340
Pot,Hyperkalemia,any grade increase,n=351
Pot,Hyperkalemia,increase to Grade 3,n=350
Pot,Hyperkalemia,increase to Grade 4,n=351
Pot,Hypokalemia,any grade increase,n=3512
Pot,Hypokalemia,increase to Grade 3,n=353
Pot,Hypokalemia,increase to Grade 4,n=351
Mg,Hypermagnesemia,any grade increase,n=341
Mg,Hypermagnesemia,increase to Grade 3,n=340
Mg,Hypermagnesemia,increase to Grade 4,n=340
Mg,Hypomagnesemia,any grade increase,n=349
Mg,Hypomagnesemia,increase to Grade 3,n=340
Mg,Hypomagnesemia,increase to Grade 4,n=341
Phosphate,any grade increase,n=358
Phosphate,increase to Grade 3,n=350
Phosphate,increase to Grade 4,n=350
Sod,Hypernatremia,any grade increase,n=350
Sod,Hypernatremia,increase to Grade 3,n=350
Sod,Hypernatremia,increase to Grade 4,n=350
Sod,Hyponatremia,any grade increase,n=354
Sod,Hyponatremia,increase to Grade 3,n=350
Sod,Hyponatremia,increase to Grade 4,n=351
Urate,any grade increase,n=351
Urate,increase to Grade 3,n=350
Urate,increase to Grade 4,n=351
Ca,Hypercalcemia,any grade increase,n=358
Ca,Hypercalcemia,increase to Grade 3,n=352
Ca,Hypercalcemia,increase to Grade 4,,n=351
Ca,Hypocalcemia,any grade increase,n=354
Ca,Hypocalcemia,increase to Grade 3,n=350
Ca,Hypocalcemia,increase to Grade 4,n=350
PrimaryNumber of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)

Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Gl, Hyperglycemia,any grade increase2
Gl, Hyperglycemia,increase to Grade 30
Gl, Hyperglycemia,increase to Grade 40
Gl, Hypoglycemia,any grade increase0
Gl, Hypoglycemia,increase to Grade 30
Gl, Hypoglycemia,increase to Grade 40
Albumin,any grade increase2
Albumin,increase to Grade 30
Albumin,increase to Grade 40
ALP,any grade increase1
ALP,increase to Grade 30
ALP,increase to Grade 40
ALT,any grade increase1
ALT,increase to Grade 30
ALT,increase to Grade 40
AST,any grade increase2
AST,increase to Grade 30
AST,increase to Grade 40
Total bilirubin,any grade increase2
Total bilirubin,increase to Grade 30
Total bilirubin,increase to Grade 40
CK,any grade increase1
CK,increase to Grade 30
CK,increase to Grade 40
Creatinine,any grade increase1
Creatinine,increase to Grade 30
Creatinine,increase to Grade 40
GGT,any grade increase2
GGT,increase to Grade 30
GGT,increase to Grade 40
Pot,Hyperkalemia,any grade increase0
Pot,Hyperkalemia,increase to Grade 30
Pot,Hyperkalemia,increase to Grade 40
Pot,Hypokalemia,any grade increase1
Pot,Hypokalemia,increase to Grade 30
Pot,Hypokalemia,increase to Grade 40
Mg,Hypermagnesemia,any grade increase0
Mg,Hypermagnesemia,increase to Grade 30
Mg,Hypermagnesemia,increase to Grade 40
Mg,Hypomagnesemia,any grade increase1
Mg,Hypomagnesemia,increase to Grade 30
Mg,Hypomagnesemia,increase to Grade 40
Phosphate,any grade increase2
Phosphate,increase to Grade 31
Phosphate,increase to Grade 40
Sod,Hypernatremia,any grade increase0
Sod,Hypernatremia,increase to Grade 30
Sod,Hypernatremia,increase to Grade 40
Sod,Hyponatremia,any grade increase3
Sod,Hyponatremia,increase to Grade 30
Sod,Hyponatremia,increase to Grade 40
Ca,Hypercalcemia,any grade increase4
Ca,Hypercalcemia,increase to Grade 31
Ca,Hypercalcemia,increase to Grade 40
Ca,Hypocalcemia,any grade increase1
Ca,Hypocalcemia,increase to Grade 30
Ca,Hypocalcemia,increase to Grade 40
PrimaryNumber of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1

Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
D.Bil.,decrease to low,n=1,1,4,2,2,3,4,4,3,50000000101
D.Bil.,to normal or NC, n=1,1,4,2,2,3,4,4,3,51132134333
D.Bil.,increase to high,n=1,1,4,2,2,3,4,4,3,50010100002
Chloride,decrease to low,n=1,1,4,4,4,3,4,8,3,60010211303
Chloride,to normal or NC,n=1,1,4,4,4,3,4,8,3,61134223423
Chloride,increase to high,n=1,1,4,4,4,3,4,8,3,60000000110
CO2,decrease to low,n=1,1,4,4,4,3,4,8,3,61113113222
CO2, to normal or NC,n=1,1,4,4,4,3,4,8,3,60031320514
CO2,increase to high,n=1,1,4,4,4,3,4,8,3,60000001100
LDH,decrease to low,n=1,1,4,4,3,3,4,8,3,60001100000
LDH,to normal or NC,n=n=1,1,4,4,3,3,4,8,3,61122121511
LDH,increase to high,n=1,1,4,4,3,3,4,8,3,60021113325
T.Pro,decrease to low,n=1,1,4,4,4,3,4,8,3,60001000220
T.Pro,to normal or NC,n=1,1,4,4,4,3,4,8,3,61143223614
T.Pro,increase to high,n=1,1,4,4,4,3,4,8,3,60000211002
BUN,decrease to low,n=1,1,4,4,4,3,4,8,3,60010200102
BUN,to normal or NC,n=1,1,4,4,4,3,4,8,3,61123233523
BUN,increase to high,n=1,1,4,4,4,3,4,8,3,60011001211
PrimaryNumber of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)

Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
D.Bil.,decrease to low,n=302
D.Bil., to normal or no change,n=3020
D.Bil.,increase to high,n=308
Chloride,decrease to low,n=357
Chloride, to normal or no change,n=3525
Chloride,increase to high,n=354
CO2,decrease to low,n=358
CO2, to normal or no change,n=3523
CO2,increase to high,n=355
LDH,decrease to low,n=351
LDH, to normal or no change,n=3517
LDH,increase to high,n=3517
T.Pro,decrease to low,n=3511
T.Pro, to normal or no change,n=3518
T.Pro,increase to high,n=357
BUN,decrease to low,n=358
BUN, to normal or no change,n=3523
BUN,increase to high,n=354
PrimaryNumber of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)

Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
D.Bil.,decrease to low,n=20
D.Bil., to normal or no change,n=22
D.Bil.,increase to high,n=20
Chloride,decrease to low,n=51
Chloride, to normal or no change,n=52
Chloride,increase to high,n=52
CO2,decrease to low,n=52
CO2, to normal or no change,n=53
CO2,increase to high,n=50
LDH,decrease to low,n=50
LDH, to normal or no change,n=54
LDH,increase to high,n=51
T.Pro,decrease to low,n=51
T.Pro, to normal or no change,n=54
T.Pro,increase to high,n=50
PrimaryNumber of Participants With Grade Change From Baseline in Hematology Data-Part 1

Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Hb, Hb increased, any grade increase0000000010
Hb, Hb increased, increase to Grade 30000000000
Hb, Hb increased, increase to Grade 40000000000
Hb,Anemia, any grade increase1112221324
Hb, Anemia, increase to Grade 30111110001
Hb, Anemia, increase to Grade 40000000000
Lymph, Lymph count increased, any grade increase0000000000
Lymph, Lymph count increased, increase to Grade 30000000000
Lymph, Lymph count increased, increase to Grade 40000000000
Lymph, Lymph count decreased, any grade increase0010212423
Lymph, Lymph count decreased, increase to Grade 30000000401
Lymph, Lymph count decreased, increase to Grade 40000100002
Neutro, any grade increase1121021423
Neutro, increase to Grade 30111000010
Neutro, increase to Grade 40000000001
PC, any grade increase1123112636
PC, increase to Grade 31002010024
PC, increase to Grade 40010100001
Leuko, Leukocytosis, any grade increase0000000000
Leuko, Leukocytosis, increase to Grade 30000000000
Leuko, Leukocytosis, increase to Grade 40000000000
Leuko, Leuko decreased, any grade increase1131113123
Leuko, Leuko decreased, increase to Grade 30000000002
Leuko, Leuko decreased, increase to Grade 40000000000
PrimaryNumber of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)

Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Hb, Hb increased, any grade increase1
Hb, Hb increased, increase to Grade 30
Hb, Hb increased, increase to Grade 40
Hb,Anemia, any grade increase18
Hb, Anemia, increase to Grade 37
Hb, Anemia, increase to Grade 40
Lymph, Lymph count increased, any grade increase3
Lymph, Lymph count increased, increase to Grade 30
Lymph, Lymph count increased, increase to Grade 40
Lymph, Lymph count decreased, any grade increase18
Lymph, Lymph count decreased, increase to Grade 38
Lymph, Lymph count decreased, increase to Grade 42
Neutro, any grade increase15
Neutro, increase to Grade 32
Neutro, increase to Grade 45
PC, any grade increase32
PC, increase to Grade 313
PC, increase to Grade 43
Leuko, Leukocytosis, any grade increase0
Leuko, Leukocytosis, increase to Grade 30
Leuko, Leukocytosis, increase to Grade 40
Leuko, Leuko decreased, any grade increase16
Leuko, Leuko decreased, increase to Grade 34
Leuko, Leuko decreased, increase to Grade 41
PrimaryNumber of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)

Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Hb, Hb increased, any grade increase, n=60
Hb, Hb increased, increase to Grade 3, n=60
Hb, Hb increased, increase to Grade 4, n=60
Hb,Anemia, any grade increase, n=62
Hb, Anemia, increase to Grade 3, n=60
Hb, Anemia, increase to Grade 4, n=60
Lymph,Lymph count increased,any grade increase,n=60
Lymph,Lymph count increased,increase to Grade3,n=60
Lymph,Lymph count increased,increase to Grade4,n=60
Lymph,Lymph count decreased,any grade increase,n=65
Lymph,Lymph count decreased,increase to Grade3,n=63
Lymph,Lymph count decreased,increase to Grade4,n=62
Neutro, any grade increase, n=60
Neutro, increase to Grade 3, n=60
Neutro, increase to Grade 4, n=60
PC, any grade increase, n=53
PC, increase to Grade 3, n=50
PC, increase to Grade 4, n=51
Leuko, Leukocytosis, any grade increase, n=60
Leuko, Leukocytosis, increase to Grade 3, n=60
Leuko, Leukocytosis, increase to Grade 4, n=60
Leuko, Leuko decreased, any grade increase, n=64
Leuko, Leuko decreased, increase to Grade 3, n=60
Leuko, Leuko decreased, increase to Grade 4, n=60
PrimaryNumber of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1

Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Baso,decrease to low,n=1,1,4,4,4,3,4,8,3,60000000002
Baso, to normal or NC,n=1,1,4,4,4,3,4,8,3,61144433833
Baso,increase to high,n=1,1,4,4,4,3,4,8,3,60000001003
Eosino,decrease to low,n=1,1,4,4,4,3,4,8,3,61010010001
Eosino,to normal or NC,n=1,1,4,4,4,3,4,8,3,60134424834
Eosino,increase to high,n=1,1,4,4,4,3,4,8,3,60000000002
Hct,decrease to low,n=1,1,4,4,4,3,4,8,3,60001010110
Hct, to normal or NC,n=1,1,4,4,4,3,4,8,3,61143424716
Hct,increase to high,n=1,1,4,4,4,3,4,8,3,60000000010
MCH,decrease to low,n=1,1,4,4,4,3,4,8,3,60000003311
MCH, to normal or NC,n=1,1,4,4,4,3,4,8,3,61144331525
MCH,increase to high,n=1,1,4,4,4,3,4,8,3,60000100100
MCHC,decrease to low,n=1,1,4,4,4,3,4,8,3,60100011311
MCHC, to normal or NC,n=1,1,4,4,4,3,4,8,3,61043423525
MCHC,increase to high,n=1,1,4,4,4,3,4,8,3,60001000000
MCV,decrease to low,n=1,1,4,4,4,3,4,8,3,60000002011
MCV, to normal or NC,n=1,1,4,4,4,3,4,8,3,61044432825
MCV,increase to high,n=1,1,4,4,4,3,4,8,3,60100000000
Mono,decrease to low,n=1,1,4,4,4,3,4,8,3,60000000100
Mono, to normal or NC,n=1,1,4,4,4,3,4,8,3,60133432501
Mono,increase to high,n=1,1,4,4,4,3,4,8,3,61011002335
Erythro,decrease to low,n=1,1,4,4,4,3,4,8,3,60000000200
Erythro, to normal or NC,n=1,1,4,4,4,3,4,8,3,61144433626
Erythro,increase to high,n=1,1,4,4,4,3,4,8,3,60000001010
Reticu,decrease to low,n=1,1,3,3,2,1,4,8,2,60010000311
Reticu,to normal or NC,n=1,1,3,3,2,1,4,8,2,61113101414
Reticu,increase to high,n=1,1,3,3,2,1,4,8,2,60010113101
PrimaryNumber of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)

Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Baso,decrease to low,n=350
Baso, to normal or NC,n=3533
Baso,increase to high,n=352
Eosino,decrease to low,n=357
Eosino,to normal or NC,n=3526
Eosino,increase to high,n=352
Hct,decrease to low,n=354
Hct, to normal or NC,n=3531
Hct,increase to high,n=350
MCH,decrease to low,n=357
MCH, to normal or NC,n=3528
MCH,increase to high,n=351
MCHC,decrease to low,n=355
MCHC, to normal or NC,n=3528
MCHC,increase to high,n=352
MCV,decrease to low,n=356
MCV, to normal or NC,n=3528
MCV,increase to high,n=351
Mono,decrease to low,n=354
Mono, to normal or NC,n=3518
Mono,increase to high,n=3514
Erythro,decrease to low,n=352
Erythro, to normal or NC,n=3531
Erythro,increase to high,n=352
Reticu,decrease to low,n=2810
Reticu, to normal or NC,n=2814
Reticu,increase to high,n=288
PrimaryNumber of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)

Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Baso,decrease to low,n=60
Baso, to normal or NC,n=66
Baso,increase to high,n=60
Eosino,decrease to low,n=60
Eosino,to normal or NC,n=66
Eosino,increase to high,n=60
Hct,decrease to low,n=61
Hct, to normal or NC,n=65
Hct,increase to high,n=60
MCH,decrease to low,n=61
MCH, to normal or NC,n=65
MCH,increase to high,n=60
MCHC,decrease to low,n=61
MCHC, to normal or NC,n=65
MCHC,increase to high,n=60
MCV,decrease to low,n=62
MCV, to normal or NC,n=64
MCV,increase to high,n=60
Mono,decrease to low,n=60
Mono, to normal or NC,n=64
Mono,increase to high,n=62
Erythro,decrease to low,n=62
Erythro, to normal or NC,n=64
Erythro,increase to high,n=60
Reticu,decrease to low,n=50
Reticu, to normal or NC,n=54
Reticu,increase to high,n=51
PrimaryNumber of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1

Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
OB,No change/decreased, n=1,1,4,4,2,3,3,8,3,61133121525
OB,Increase to small, n=1,1,4,4,2,3,3,8,3,60010112310
OB,Increase to moderate, n=1,1,4,4,2,3,3,8,3,60000000000
OB,Increase to large, n=1,1,4,4,2,3,3,8,3,60001000001
Pro,No change/decreased, n=1,1,4,3,2,3,4,5,3,51033213111
Pro,Increase to trace, n=1,1,4,3,2,3,4,5,3,50010010421
Pro,Increase to 1+, n=1,1,4,3,2,3,4,5,3,50000001001
Pro,Increase to 2+, n=1,1,4,3,2,3,4,5,3,50000010001
Pro,Increase to 3+, n=1,1,4,3,2,3,4,5,3,50000000000
Pro,Unknown, n=1,1,4,3,2,3,4,5,3,50100000001
PrimaryNumber of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)

Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
OB,No change/decreased, n=3318
OB,Increase to small, n=3314
OB,Increase to moderate, n=331
OB,Increase to large, n=330
Pro,No change/decreased, n=3115
Pro,Increase to trace, n=3111
Pro,Increase to 1+, n=311
Pro,Increase to 2+, n=310
Pro,Increase to 3+, n=310
Pro,Unknown, n=314
PrimaryNumber of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)

Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.

Time frame:
Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
OB,No change/decreased, n=54
OB,Increase to small, n=50
OB,Increase to moderate, n=50
OB,Increase to large, n=51
Pro,No change/decreased, n=43
Pro,Increase to trace, n=41
Pro,Increase to 1+, n=40
Pro,Increase to 2+, n=40
Pro,Increase to 3+, n=40
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2 and 3)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg
Grams per dayPart 1: GSK2857916 0.06 mg/kg
Day 1 (Cycle 2)-0.0 ± NA
Day 1 (Cycle 3)0.3 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg
Grams per dayPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.03 mg/kg
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg0.4 ± 0.72—
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Grams per dayPart 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 2)-0.0 ± NA
Day 1 (Cycle 3)-0.0 ± NA
Day 1 (Cycle 4)88.1 ± NA
Day 1 (Cycle 5)-0.1 ± NA
Day 1 (Cycle 6)-0.0 ± NA
Day 1 (Cycle 7)-0.0 ± NA
Day 1 (Cycle 8)-0.1 ± NA
Day 1 (Cycle 9)-0.1 ± NA
Day 1 (Cycle 10)-0.1 ± NA
Day 1 (Cycle 12)-0.1 ± NA
Day 1 (Cycle 13)-0.1 ± NA
Day 1 (Cycle 14)-0.1 ± NA
Day 1 (Cycle 15)-0.1 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Grams per dayPart 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 2), n=20.0 ± 0.04
Day 1 (Cycle 3), n=10.8 ± NA
Day 1 (Cycle 5), n=10.1 ± NA
Day 1 (Cycle 6), n=10.1 ± NA
Day 1 (Cycle 7), n=10.1 ± NA
Day 1 (Cycle 8), n=10.1 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Grams per dayPart 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 2), n=20.2 ± 0.35
Day 1 (Cycle 3), n=2-0.1 ± 0.07
Day 1 (Cycle 4), n=1-0.1 ± NA
Day 1 (Cycle 5), n=10.0 ± NA
Day 1 (Cycle 6), n=10.2 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Grams per dayPart 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 2), n=3-0.1 ± 0.48
Day 1 (Cycle 3), n=3-30.3 ± 51.72
Day 1 (Cycle 4), n=4-22.4 ± 45.06
Day 1 (Cycle 5), n=30.2 ± 1.42
Day 1 (Cycle 6), n=2-0.6 ± 0.99
Day 1 (Cycle 7), n=2-0.6 ± 1.16
Day 1 (Cycle 8), n=2-0.6 ± 1.06
Day 1 (Cycle 11), n=1-1.4 ± NA
Day 1 (Cycle 12), n=1-1.4 ± NA
Day 1 (Cycle 13), n=1-1.4 ± NA
Day 1 (Cycle 14), n=1-1.4 ± NA
Day 1 (Cycle 16), n=1-1.3 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Grams per dayPart 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 2), n=40.8 ± 1.54
Day 1 (Cycle 3), n=2-0.2 ± 0.31
Day 1 (Cycle 4), n=2-0.2 ± 0.38
Day 1 (Cycle 5), n=10.0 ± NA
Day 1 (Cycle 6), n=2-0.2 ± 0.33
Day 1 (Cycle 7), n=10.2 ± NA
Day 1 (Cycle 8), n=1-0.5 ± NA
Day 1 (Cycle 10), n=1-0.4 ± NA
Day 1 (Cycle 12), n=1-0.5 ± NA
Day 1 (Cycle 13), n=1-0.5 ± NA
Day 1 (Cycle 14), n=1-0.4 ± NA
Day 1 (Cycle 15), n=1-0.5 ± NA
Day 1 (Cycle 16), n=1-0.5 ± NA
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Grams per dayPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Day 1 (Cycle 2), n=2,5-0.6 ± 0.830.0 ± 0.45
Day 1 (Cycle 3), n=2,4-0.6 ± 0.81-0.0 ± 0.23
Day 1 (Cycle 4), n=2,4-0.7 ± 0.79-0.1 ± 0.25
Day 1 (Cycle 5), n=2,4-0.6 ± 0.78-0.1 ± 0.46
Day 1 (Cycle 6), n=2,4-0.6 ± 0.80-0.0 ± 0.33
Day 1 (Cycle 7), n=2,4-0.6 ± 0.79-0.1 ± 0.48
Day 1 (Cycle 8), n=2,2-0.6 ± 0.800.1 ± 0.15
Day 1 (Cycle 9), n=1,2-1.1 ± NA0.2 ± 0.33
Day 1 (Cycle 10), n=1,2-1.1 ± NA-0.0 ± 0.03
Day 1 (Cycle 11), n=1,2-1.2 ± NA-0.1 ± 0.06
Day 1 (Cycle 12), n=1,2-1.2 ± NA0.0 ± 0.13
Day 1 (Cycle 13), n=1,2-1.1 ± NA0.0 ± 0.09
Day 1 (Cycle 14), n=1,2-1.0 ± NA0.3 ± 0.11
Day 1 (Cycle 15), n=1,2-1.1 ± NA0.1 ± 0.10
Day 1 (Cycle 16), n=1,2-1.2 ± NA0.4 ± 0.11
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)

Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented

Time frame:
Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Grams per dayPart 2: GSK2857916 3.40 mg/kg (MM)
Day 1 (Cycle 2), n=24-0.5 ± 1.21
Day 1 (Cycle 3), n=18-0.7 ± 1.29
Day 1 (Cycle 4), n=13-0.7 ± 1.65
Day 1 (Cycle 5), n=15-0.7 ± 1.66
Day 1 (Cycle 6), n=14-0.8 ± 1.69
Day 1 (Cycle 7), n=14-0.9 ± 1.56
Day 1 (Cycle 8), n=16-0.7 ± 1.53
Day 1 (Cycle 9), n=13-0.5 ± 1.01
Day 1 (Cycle 10), n=12-0.4 ± 1.06
Day 1 (Cycle 11), n=10-0.4 ± 1.01
Day 1 (Cycle 12), n=10-0.4 ± 1.11
Day 1 (Cycle 13), n=9-0.4 ± 1.27
Day 1 (Cycle 14), n=9-0.4 ± 1.25
Day 1 (Cycle 15), n=9-0.4 ± 1.30
Day 1 (Cycle 16), n=9-0.3 ± 1.35
PrimaryChange From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)

Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.

Time frame:
Baseline and Day 1 (Cycle 2)
Reported as:
Mean · Grams per day
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)
Grams per dayPart 2: GSK2857916 3.40 mg/kg (NHL)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)0.0 ± 0.18
SecondaryArea Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Hours*nanogram per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1—215803.06 ± NA767285.51 ± 49.51632339.28 ± 101.142991509.97 ± 72.129235256.20 ± 46.6518469186.92 ± NA—8355209.26 ± 25.29
SecondaryAUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Hours*nanogram per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1—200467.82 ± NA633446.78 ± 35.42729443.84 ± 91.222389114.19 ± 51.124448319.69 ± 79.519892863.42 ± 51.8123121531.16 ± 6.599738914.76 ± 38.82
SecondaryAUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Hours*nanogram per milliliter
Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Hours*nanogram per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 144260.79 ± NA178485.20 ± NA637783.48 ± 35.67694825.13 ± 107.502170746.96 ± 59.814492292.65 ± 82.0010093784.72 ± 54.2019239850.61 ± 53.1510131666.86 ± 47.32
SecondaryAUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryClearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Milliliter per hour
Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Milliliter per hourPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1—28.27 ± NA10.53 ± 58.9425.01 ± 88.6115.10 ± 75.168.46 ± 27.4611.68 ± NA—38.84 ± 37.53
SecondaryCL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryMaximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Nanograms per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1429.00 ± NA1323.00 ± NA2956.77 ± 18.454548.10 ± 20.2711876.46 ± 24.0823050.05 ± 23.0543774.18 ± 45.1868128.02 ± 20.84117385.57 ± 24.14
SecondaryCmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryTrough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)
Reported as:
Geometric mean · Nanograms per milliliter
Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Nanograms per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6—NA ± NA381.95 ± 105.551331.11 ± 44.434307.00 ± NA3720.27 ± 113.7111420.61 ± 35.7028134.46 ± 35.972301.18 ± 75.69
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5—NA ± NA—1672.18 ± 28.767259.00 ± NA9510.04 ± 104.5612791.83 ± 46.8212719.77 ± 6.212643.94 ± 123.56
SecondaryCtrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Nanograms per milliliterPart 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 1,n=83726.78 ± 49.92
Day 1, Cycle 2,n=411352.94 ± 268.64
Day 1, Cycle 4,n=311121.73 ± 59.75
SecondaryTerminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Hours
Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
HoursPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1—126.18 ± NA188.20 ± 37.41117.82 ± 76.00198.48 ± 50.42264.93 ± 46.73308.39 ± NA—103.74 ± 17.29
Secondaryt1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryVolume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Milliliter
Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
MilliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1—5239 ± NA2900 ± 29.044286 ± 31.294388 ± 21.993224 ± 22.375156 ± NA—5215 ± 19.41
SecondaryVss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryTime to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Median · Hours
Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
HoursPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 12.080 (2.08 to 2.08)4.080 (4.08 to 4.08)1.185 (1.00 to 2.00)3.085 (2.00 to 8.78)1.000 (1.00 to 4.00)2.050 (2.00 to 2.08)1.000 (0.50 to 24.00)6.920 (2.02 to 8.78)1.560 (0.95 to 2.07)
SecondaryTmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryCtrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Nanograms per milliliterPart 2: GSK2857916 3.40 mg/kg (MM)
Day 1, Cycle 1,n=283486.49 ± 85.71
Day 1, Cycle 2,n=185799.89 ± 66.52
Day 1, Cycle 4,n=126184.46 ± 103.79
SecondaryCtrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2

Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)
Reported as:
Mean · Nanograms per milliliter
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Nanograms per milliliterPart 2: GSK2857916 3.40 mg/kg (NHL)
Cycle 1 Day 1, n=50.0 ± 0.00
Cycle 2 Day 1, n=43761.8 ± 2225.57
Cycle 3 Day 1, n=18401.0 ± NA
SecondaryAUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Hours*picogram per milliliter
AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Hours*picogram per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1——1157.46 ± NA1623.87 ± 41.4314681.62 ± 91.8820787.48 ± 209.2772608.00 ± 17.60119177.30 ± 35.77181147.61 ± 94.32
SecondaryAUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryCmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Geometric mean · Picograms per milliliter
Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Picograms per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1——51.50 ± NA91.49 ± 31.76260.62 ± 15.70488.29 ± 38.511054.02 ± 18.961199.86 ± 35.112544.02 ± 87.04
SecondaryCmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryCtrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)
Reported as:
Geometric mean · Picograms per milliliter
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Picograms per milliliterPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6—NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5—NA ± NA—NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryCtrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Reported as:
Geometric mean · Picograms per milliliter
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Picograms per milliliterPart 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 1,n=8NA ± NA
Day 1, Cycle 2,n=4NA ± NA
Day 1, Cycle 4,n=3NA ± NA
SecondaryTmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

Time frame:
Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Reported as:
Median · Hours
Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
HoursPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1——49.130 (49.13 to 49.13)23.875 (9.00 to 24.63)24.730 (24.00 to 25.83)9.050 (8.78 to 22.83)8.750 (7.75 to 24.00)23.700 (23.17 to 24.97)24.040 (7.83 to 25.00)
SecondaryTmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg

Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.

Time frame:
Pre-dose and EOI of Day 1 (Cycle 1)

No measurements were reported for this outcome.

SecondaryNumber of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1

Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

Time frame:
Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 10000000000
SecondaryNumber of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)

Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

Time frame:
Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)0
SecondaryNumber of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)

Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.

Time frame:
Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)0
SecondaryNumber of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1

Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.

Time frame:
Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Baseline,screening,pos, n=1,1,4,4,4,3,4,7,2,60000000000
Baseline,screening,neg, n=1,1,4,4,4,3,4,7,2,61144434726
Baseline,neg,conclusive,n=1,1,4,4,4,3,4,7,2,60000000600
Cycle 2 Day 1,screening,pos, n=0,1,4,2,2,3,3,8,3,5—000000000
Cycle 2 Day 1,screening,neg, n=0,1,4,2,2,3,3,8,3,5—142233835
Cycle 2 Day 1,neg,conclusive,n=0,1,4,2,2,3,3,8,3,5—132233825
Cycle 3 Day 1,screening,pos, n=0,1,0,2,2,1,2,4,3,6—0—0000000
Cycle 3 Day 1,screening,neg, n=0,1,0,2,2,1,2,4,3,6—1—2212436
Cycle 3 Day 1,neg,conclusive,n=0,1,0,2,2,1,2,4,3,6—1—2212204
Cycle 4 Day 1,screening,pos, n=0,0,0,0,0,0,0,0,0,1—————————0
Cycle 4 Day 1,screening,neg, n=0,0,0,0,0,0,0,0,0,1—————————1
Cycle 4 Day 1,neg,conclusive,n=0,0,0,0,0,0,0,0,0,1—————————0
Cycle 6 Day 1,screening,pos, n=0,0,0,1,1,1,2,3,3,3———0000010
Cycle 6 Day 1,screening,neg, n=0,0,0,1,1,1,2,3,3,3———1112323
Cycle 6 Day 1,confirming,pos,n=0,0,0,0,0,0,0,0,1,0————————0—
Cycle 6 Day 1,confirming,neg,n=0,0,0,0,0,0,0,0,1,0————————1—
Cycle 6 Day 1,neg,conclusive,n=0,0,0,1,1,1,2,3,3,3———0000000
Cycle 9 Day 1,screening,pos, n=0,0,0,1,0,0,1,1,2,2———0——0000
Cycle 9 Day 1,screening,neg, n=0,0,0,1,0,0,1,1,2,2———1——1122
Cycle 9 Day 1,neg,conclusive,n=0,0,0,1,0,0,1,1,2,2———0——0000
Cycle 12 Day 1,screening,pos,n=0,0,0,1,0,0,1,1,1,3———0——0001
Cycle 12 Day 1,screening,neg,n=0,0,0,1,0,0,1,1,1,3———1——1112
Cycle 12 Day1,confirming,pos,n=0,0,0,0,0,0,0,0,0,1—————————0
Cycle 12 Day1,confirming,neg,n=0,0,0,0,0,0,0,0,0,1—————————1
Cycle 12 Day1,neg,conclusive,n=0,0,0,1,0,0,1,1,1,3———0——0000
Cycle 16 Day 1,screening,pos,n=0,0,0,0,0,0,1,1,1,2——————0000
Cycle 16 Day 1,screening,neg,n=0,0,0,0,0,0,1,1,1,2——————1112
Cycle 16 Day1,neg,conclusive,n=0,0,0,0,0,0,1,1,1,2——————0000
End of study,screening,pos,n=1,1,4,4,4,3,3,6,1,50001000000
End of study,screening,neg,n=1,1,4,4,4,3,3,6,1,51143433615
End of study,confirming,pos,n=0,0,0,1,0,0,0,0,0,0———0——————
End of study,confirming,neg,n=0,0,0,1,0,0,0,0,0,0———1——————
End of study,neg,conclusive,n=1,1,4,4,4,3,3,6,1,50000000000
SecondaryNumber of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)

Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

Time frame:
Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
Baseline, screening, positive, n=302
Baseline, screening, negative n=3028
Baseline, confirming, positive, n=20
Baseline, confirming, negative, n=22
Baseline, negative, conclusive, n=3021
Cycle 2, Day 1, screening, positive, n=313
Cycle 2, Day 1, screening, negative, n=3128
Cycle 2, Day 1, confirming, positive, n=30
Cycle 2, Day 1, confirming, negative, n=33
Cycle 2, Day 1, negative, conclusive, n=3127
Cycle 3, Day 1, screening, positive, n=230
Cycle 3, Day 1, screening, negative, n=2323
Cycle 3, Day 1, negative, conclusive, n=2314
Cycle 6, Day 1, screening, positive, n=174
Cycle 6, Day 1, screening, negative, n=1713
Cycle 6, Day 1, confirming, positive, n=40
Cycle 6, Day 1, confirming, negative, n=44
Cycle 6, Day 1, negative, conclusive, n=170
Cycle 7, Day 1, screening, positive, n=10
Cycle 7, Day 1, screening, negative, n=11
Cycle 7, Day 1, negative, conclusive, n=10
Cycle 9, Day 1, screening, positive, n=162
Cycle 9, Day 1, screening, negative, n=1614
Cycle 9, Day 1, confirming, positive, n=20
Cycle 9, Day 1, confirming, negative, n=22
Cycle 9, Day 1, negative, conclusive, n=160
Cycle 11, Day 1, screening, positive, n=10
Cycle 11, Day 1, screening, negative, n=11
Cycle 11, Day 1, negative, conclusive, n=10
Cycle 12, Day 1, screening, positive, n=80
Cycle 12, Day 1, screening, negative, n=88
Cycle 12, Day 1, negative, conclusive, n=80
Cycle 16, Day 1, screening, positive, n=80
Cycle 16, Day 1, screening, negative, n=88
Cycle 16, Day 1, negative, conclusive, n=80
End of study, screening, positive, n=211
End of study, screening, negative, n=2120
End of study, confirming, positive, n=10
End of study, confirming, negative, n=11
End of study, negative, conclusive, n=210
SecondaryNumber of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)

Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.

Time frame:
Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
Baseline, screening, positive, n=50
Baseline, screening, negative n=55
Baseline, negative, conclusive, n=55
Cycle 2, Day 1, screening, positive, n=40
Cycle 2, Day 1, screening, negative, n=44
Cycle 2, Day 1, negative, conclusive, n=44
Cycle 3, Day 1, screening, positive, n=21
Cycle 3, Day 1, screening, negative, n=21
Cycle 3, Day 1, confirming, positive, n=10
Cycle 3, Day 1, confirming, negative, n=11
Cycle 3, Day 1, negative, conclusive, n=21
End of study, screening, positive, n=40
End of study, screening, negative, n=44
End of study, negative, conclusive, n=40
SecondaryOverall Response Rate (ORR)- Part 1

ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).

Time frame:
From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Overall Response Rate (ORR)- Part 10000011133
SecondaryORR-Part 2 (MM)

ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.

Time frame:
From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)
Reported as:
Count of participants · Participants
ORR-Part 2 (MM)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
ORR-Part 2 (MM)21
SecondaryORR-Part 2 (NHL)

Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.

Time frame:
From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)
Reported as:
Count of participants · Participants
ORR-Part 2 (NHL)
ParticipantsPart 2: GSK2857916 3.40 mg/kg (NHL)
ORR-Part 2 (NHL)0
SecondaryClinical Benefit Rate (CBR)- Part 1

CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).

Time frame:
From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)
Reported as:
Count of participants · Participants
Clinical Benefit Rate (CBR)- Part 1
ParticipantsPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kg
Clinical Benefit Rate (CBR)- Part 10001112235
SecondaryCBR- Part 2

CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.

Time frame:
From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)
Reported as:
Count of participants · Participants
CBR- Part 2
ParticipantsPart 2: GSK2857916 3.40 mg/kg (MM)
CBR- Part 221

Adverse events

Collected over SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: GSK2857916 0.03 mg/kg0/1 (0%)0/1 (0%)1/1 (100%)
Part 1: GSK2857916 0.06 mg/kg0/1 (0%)0/1 (0%)1/1 (100%)
Part 1: GSK2857916 0.12 mg/kg0/4 (0%)1/4 (25%)4/4 (100%)
Part 1: GSK2857916 0.24 mg/kg0/4 (0%)1/4 (25%)4/4 (100%)
Part 1: GSK2857916 0.48 mg/kg0/4 (0%)1/4 (25%)3/4 (75%)
Part 1: GSK2857916 0.96 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Part 1: GSK2857916 1.92 mg/kg0/4 (0%)2/4 (50%)4/4 (100%)
Part 1: GSK2857916 2.50 mg/kg1/8 (12.5%)4/8 (50%)8/8 (100%)
Part 1: GSK2857916 3.40 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1: GSK2857916 4.60 mg/kg1/6 (16.7%)3/6 (50%)6/6 (100%)
Part 2: GSK2857916 3.40 mg/kg (MM)5/35 (14.3%)17/35 (48.6%)35/35 (100%)
Part 2: GSK2857916 3.40 mg/kg (NHL)3/6 (50%)3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)
Pharyngeal haemorrhageRespiratory, thoracic and mediastinal disorders0/10/10/40/40/40/30/40/81/30/60/350/6
PneumoniaInfections and infestations0/10/10/40/40/40/30/41/81/30/65/350/6
Hyperviscosity syndromeBlood and lymphatic system disorders0/10/11/40/40/40/30/40/80/30/60/350/6
HypotensionVascular disorders0/10/10/41/40/40/30/40/80/30/60/350/6
Limbal stem cell deficiencyEye disorders0/10/10/40/40/40/31/40/80/30/60/350/6
NauseaGastrointestinal disorders0/10/10/40/41/40/30/40/80/30/60/350/6
PyrexiaGeneral disorders0/10/10/41/40/40/30/40/80/31/61/350/6
Spinal cord compressionNervous system disorders0/10/10/40/40/40/31/40/80/30/60/350/6
VomitingGastrointestinal disorders0/10/10/40/41/40/30/40/80/30/60/350/6
BabesiosisInfections and infestations0/10/10/40/40/40/30/40/80/31/60/350/6
Most frequent other events
Showing 10 of 178
Most frequent other events
EventPart 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)
AnaemiaBlood and lymphatic system disorders0/11/11/41/40/42/31/43/80/33/610/351/6
DiarrhoeaGastrointestinal disorders0/11/11/40/40/40/30/41/81/31/610/351/6
FatigueGeneral disorders1/10/11/42/41/42/31/43/82/34/68/351/6
HyperuricaemiaMetabolism and nutrition disorders0/11/10/40/40/40/30/40/80/30/60/350/6
NeutropeniaBlood and lymphatic system disorders1/11/11/41/40/40/30/41/80/31/62/350/6
Osteonecrosis of jawMusculoskeletal and connective tissue disorders1/10/10/40/40/40/30/40/80/30/60/350/6
ThrombocytopeniaBlood and lymphatic system disorders1/11/11/41/41/40/31/41/82/35/69/350/6
Vision blurredEye disorders0/10/10/40/40/40/33/42/83/34/618/352/6
VomitingGastrointestinal disorders0/11/10/40/40/40/30/40/81/32/62/350/6
NauseaGastrointestinal disorders0/10/12/42/41/40/33/43/82/34/611/351/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)Total
Mean49.0 ± NA71.0 ± NA56.5 ± 3.3258.5 ± 8.3560.0 ± 10.8958.7 ± 13.0565.3 ± 4.7962.6 ± 11.0448.0 ± 8.1954.8 ± 10.1160.5 ± 7.9360.2 ± 9.8159.6 ± 8.90
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)Total
Female103221251118339
Male011222232517340
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: GSK2857916 0.03 mg/kgPart 1: GSK2857916 0.06 mg/kgPart 1: GSK2857916 0.12 mg/kgPart 1: GSK2857916 0.24 mg/kgPart 1: GSK2857916 0.48 mg/kgPart 1: GSK2857916 0.96 mg/kgPart 1: GSK2857916 1.92 mg/kgPart 1: GSK2857916 2.50 mg/kgPart 1: GSK2857916 3.40 mg/kgPart 1: GSK2857916 4.60 mg/kgPart 2: GSK2857916 3.40 mg/kg (MM)Part 2: GSK2857916 3.40 mg/kg (NHL)Total
Race — Black or African American00010004005010
Race — Arabic/North African Heritage0000001001002
Race — White/Caucasian/European Heritage114343343528665
Race — Japanese Heritage0000000000101
Race — South East Asian Heritage0000000000101
08

Study locations

9 sites
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7600, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Dallas, Texas 75390-8565, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    London, NW1 2BU, United Kingdom
09

References and documents

Publications

  • Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6. PubMed 30894515 ↗
  • Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12. PubMed 30442502 ↗
  • Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187-99. doi: 10.2217/imt.15.77. Epub 2015 Sep 15. PubMed 26370838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Aug 2018, 49 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 49 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2014
First posted
Feb 17, 2014
StartActual
Jul 29, 2014
Primary completionActual
Aug 31, 2018
CompletionActual
Aug 1, 2019
Results first posted
Sep 26, 2019
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02064387
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 17, 2014
Start date
Jul 29, 2014
Primary completion
Aug 31, 2018
Completion
Aug 1, 2019
Results posted
Sep 26, 2019
Last update
Aug 11, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion